Table 1 Summarized of the treatment course of the PVOD patient
From: Good response to PAH-targeted drugs in a PVOD patient carrying Biallelic EIF2AK4 mutation
Time of Admission | 2015.7 | 2016.3 | 2017.3 | 2018.1 | 2018.4 |
|---|---|---|---|---|---|
SaO2(pre-treatment, 21% O2) | 88 | 89 | 90 | 88 | 89 |
SaO2(%) (post-treatment, 21% O2) | 96 | 95 | 96 | 94 | 96 |
NT-proBNP (ng/ml, pre-treatment | 3590 | 5080 | 24,389 | 9423 | 3957 |
NT-proBNP (ng/ml, post-treatment | 980 | 746 | 890 | 1020 | 920 |
Functional class (NYHA, pre-treatment) | III | III | III | IV | III |
Functional class (NYHA, post-treatment) | II | II | II | II | II |
PAH-targeted drugs (in hospital) | Bosentan | Ambrisentan+Sildenafil | Ambrisentan+Sildenafil | Ambrisentan+Sildenafil+Treprostinil injection | Ambrisentan+Sildenafil+Treprostinil injection |
PAH-targeted drugs (discharge) | Bosentan (changed to Ambrisentan, because of liver dysfunction 4 months later), Ambrisentan | Ambrisentan+Sildenafil | Ambrisentan+Sildenafil | Ambrisentan+Sildenafil | Ambrisentan+Sildenafil |